These results support the clinical utility of PI3K pathway inhibition in combination with fulvestrant to treat breast cancers with prolonged estrogen deprivation, such as ER+ breast cancers that recur after adjuvant AI or metastatic ER+ breast cancer that progresses on AI therapy. Here, PIK3CB is linked to breast cancer.